NO309675B1 - Kombinert vaksine omfattende hepatitt B-overflateantigen - Google Patents

Kombinert vaksine omfattende hepatitt B-overflateantigen Download PDF

Info

Publication number: NO309675B1
Authority: NO; Norway
Prior art keywords: vaccine; hbsag; adsorbed; hepatitis; combined
Prior art date: 1992-05-23

Application number

NO944475A

Other languages

English (en)

Norwegian (no)

Other versions

NO944475L (no

NO944475D0 (no

Inventor

Jean Petre

Pierre Hauser

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-23

Filing date

1994-11-22

Publication date

2001-03-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO309675(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-05-23 Priority claimed from GB929211081A external-priority patent/GB9211081D0/en

1992-06-23 Priority claimed from GB929213308A external-priority patent/GB9213308D0/en

1994-11-22 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1994-11-22 Publication of NO944475D0 publication Critical patent/NO944475D0/no

1995-01-18 Publication of NO944475L publication Critical patent/NO944475L/no

2001-03-12 Publication of NO309675B1 publication Critical patent/NO309675B1/no

Links

229960005486 vaccine Drugs 0.000 title claims description 84
239000000427 antigen Substances 0.000 title claims description 64
108091007433 antigens Proteins 0.000 title claims description 64
102000036639 antigens Human genes 0.000 title claims description 64
208000002672 hepatitis B Diseases 0.000 title claims description 33
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 53
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 46
230000005847 immunogenicity Effects 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 18
239000002671 adjuvant Substances 0.000 claims description 17
208000005252 hepatitis A Diseases 0.000 claims description 16
238000000034 method Methods 0.000 claims description 15
201000005702 Pertussis Diseases 0.000 claims description 14
206010013023 diphtheria Diseases 0.000 claims description 13
206010043376 Tetanus Diseases 0.000 claims description 12
229940001442 combination vaccine Drugs 0.000 claims description 8
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 7
229910052782 aluminium Inorganic materials 0.000 claims description 7
238000002255 vaccination Methods 0.000 claims description 6
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
238000001179 sorption measurement Methods 0.000 claims description 5
229940066827 pertussis vaccine Drugs 0.000 claims description 4
241000606768 Haemophilus influenzae Species 0.000 claims description 3
208000000474 Poliomyelitis Diseases 0.000 claims description 3
230000036039 immunity Effects 0.000 claims description 3
230000003053 immunization Effects 0.000 claims description 3
238000002649 immunization Methods 0.000 claims description 3
238000011282 treatment Methods 0.000 claims description 3
229940124832 acellular pertussis vaccine Drugs 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims 1
239000000203 mixture Substances 0.000 description 34
229940009859 aluminum phosphate Drugs 0.000 description 28
238000009472 formulation Methods 0.000 description 19
239000012141 concentrate Substances 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000004480 active ingredient Substances 0.000 description 10
241000709721 Hepatovirus A Species 0.000 description 9
238000002474 experimental method Methods 0.000 description 8
229940031348 multivalent vaccine Drugs 0.000 description 8
239000000047 product Substances 0.000 description 8
229940032024 DPT vaccine Drugs 0.000 description 7
229940124736 hepatitis-B vaccine Drugs 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
229940029583 inactivated polio vaccine Drugs 0.000 description 6
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
230000002421 anti-septic effect Effects 0.000 description 5
229960005323 phenoxyethanol Drugs 0.000 description 5
230000004044 response Effects 0.000 description 5
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 5
241000588832 Bordetella pertussis Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 4
229940031346 monovalent vaccine Drugs 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000012360 testing method Methods 0.000 description 4
241000282412 Homo Species 0.000 description 3
229960003983 diphtheria toxoid Drugs 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
108010021711 pertactin Proteins 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229960000814 tetanus toxoid Drugs 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 2
102100031673 Corneodesmosin Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229940124914 Havrix Drugs 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
238000011795 OF1 mouse Methods 0.000 description 2
101710116435 Outer membrane protein Proteins 0.000 description 2
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229960005030 other vaccine in atc Drugs 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000004224 protection Effects 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
101710118506 69 kDa protein Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
229940124884 Engerix-B Drugs 0.000 description 1
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101710137302 Surface antigen S Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
230000002096 anti-tetanic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
229940031416 bivalent vaccine Drugs 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
239000011246 composite particle Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
229940124724 hepatitis-A vaccine Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000009021 pre-vaccination Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

NO944475A 1992-05-23 1994-11-22 Kombinert vaksine omfattende hepatitt B-overflateantigen NO309675B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB929211081A GB9211081D0 (en)	1992-05-23	1992-05-23	Vaccines
GB929213308A GB9213308D0 (en)	1992-06-23	1992-06-23	Vaccine
PCT/EP1993/001276 WO1993024148A1 (en)	1992-05-23	1993-05-15	Combined vaccines comprising hepatitis b surface antigen and other antigens

Publications (3)

Publication Number	Publication Date
NO944475D0 NO944475D0 (no)	1994-11-22
NO944475L NO944475L (no)	1995-01-18
NO309675B1 true NO309675B1 (no)	2001-03-12

Family

ID=26300928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO944475A NO309675B1 (no)	1992-05-23	1994-11-22	Kombinert vaksine omfattende hepatitt B-overflateantigen

Country Status (31)

Country	Link
US (1)	US6013264A (ja)
EP (4)	EP0642355B1 (ja)
JP (1)	JP3626996B2 (ja)
KR (1)	KR100287083B1 (ja)
CN (2)	CN1313152C (ja)
AP (1)	AP567A (ja)
AT (2)	ATE168271T1 (ja)
AU (5)	AU4315693A (ja)
CA (1)	CA2136429C (ja)
CY (1)	CY2614B2 (ja)
CZ (1)	CZ283910B6 (ja)
DE (4)	DE122010000016I1 (ja)
DK (2)	DK0835663T3 (ja)
ES (2)	ES2118963T3 (ja)
FI (1)	FI945483A (ja)
HK (2)	HK1011290A1 (ja)
HU (1)	HU220236B (ja)
IL (1)	IL105770A (ja)
LU (2)	LU91659I2 (ja)
MA (1)	MA22894A1 (ja)
MX (1)	MX9302982A (ja)
MY (1)	MY110665A (ja)
NO (1)	NO309675B1 (ja)
NZ (1)	NZ253065A (ja)
PT (1)	PT835663E (ja)
RU (1)	RU2160120C2 (ja)
SG (1)	SG48365A1 (ja)
SI (1)	SI9300271A (ja)
SK (1)	SK280702B6 (ja)
UA (1)	UA40596C2 (ja)
WO (1)	WO1993024148A1 (ja)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9503863D0 (en) *	1995-02-25	1995-04-19	Smithkline Beecham Biolog	Vaccine compositions
US6696065B1 (en)	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr) *	1995-05-24	1997-06-27	Pasteur Merieux Serums Vacc	Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) *	1995-06-23	2003-08-21	Smithkline Beecham Biologicals S.A.	Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
DE69612198T3 (de)	1995-06-23	2011-08-18	Smithkline Beecham Biologicals S.A.	Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
US20020054884A1 (en)	1995-06-23	2002-05-09	Smithkline Beecham Biologicals, Sa	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
ATE339965T1 (de) *	1996-07-02	2006-10-15	Aventis Pasteur	Vielwertige dtp-polio-impfstoffe
US20010014331A1 (en)	1996-11-07	2001-08-16	Smithkline Beecham Biologicals S.A.	Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) *	1996-11-07	1997-01-08	Smithkline Beecham Biolog	Vaccine composition
CU22629A1 (es) *	1997-03-06	2000-12-22	Ct Ingenieria Genetica Biotech	Formulaciones inmunopotenciadoras para uso vacunal
CA2288129A1 (en) *	1997-05-01	1998-11-12	Chiron Corporation	Use of virus-like particles as adjuvants
DE69735191T2 (de) *	1997-09-15	2006-10-05	Sanofi Pasteur Msd	Verfahren zur Herstellung multivalenter Impfstoffe
PL343429A1 (en) *	1998-03-09	2001-08-13	Smithkline Beecham Biolog	Combined vaccine compositions
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
US20030049268A1 (en)	1998-05-01	2003-03-13	Smithkline Beecham Biologicals S.A.	Novel composition
GB9809507D0 (en) *	1998-05-01	1998-07-01	Smithkline Beecham Biolog	Novel composition
RU2130779C1 (ru) *	1998-07-31	1999-05-27	Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
RU2130778C1 (ru) *	1998-07-31	1999-05-27	Акционерное общество закрытого типа НПК "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
AT408615B (de) *	1998-09-15	2002-01-25	Immuno Ag	Neue influenzavirus-impfstoffzusammensetzung
EP1588714A2 (en)	1998-10-16	2005-10-26	GlaxoSmithKline Biologicals S.A.	Adjuvant systems and vaccines
CN1053590C (zh) *	1998-10-19	2000-06-21	卫生部长春生物制品研究所	冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es) *	1998-12-02	2003-10-21	Ct Ingenieria Genetica Biotech	Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) *	1998-12-15	2005-12-13	Aventis Pasteur Limited	Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) *	1998-12-23	2006-08-29	Merck & Co., Inc.	Recombinant hepatitis B surface antigen
US7172762B1 (en) *	1999-01-29	2007-02-06	Pfizer Inc.	Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en)	1999-09-29	1999-12-01	Chiron Spa	Vaccine
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
KR100374813B1 (ko) *	2000-04-07	2003-03-03	녹십자백신 주식회사	디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
CZ20024224A3 (cs)	2000-06-29	2003-05-14	Glaxosmithkline Biologicals S. A.	Farmaceutický prostředek
KR100385711B1 (ko) *	2000-07-05	2003-05-27	녹십자백신 주식회사	디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) *	2001-01-10	2003-10-17	주식회사 엘지생명과학	혼합 백신의 제조 방법
NZ622900A (en) *	2001-01-23	2015-11-27	Sanofi Pasteur Inc	Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU2007200116A1 (en) *	2001-04-03	2007-02-01	Glaxosmithkline Biologicals S.A.	Vaccine composition
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) *	2001-07-26	2012-04-17	Chiron S.R.L.	Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
IL145926A0 (en)	2001-10-15	2002-07-25	Mor Research Applic Ltd	Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) *	2002-01-24	2005-02-23	Ct Ingenieria Genetica Biotech	Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
ES2379346T3 (es) *	2002-03-28	2012-04-25	Brenntag Biosector A/S	Composiciones de vacuna combinadas de ADN/proteína
GB0223355D0 (en) *	2002-10-08	2002-11-13	Chiron Spa	Vaccine
BR0315767A (pt)	2002-11-01	2005-09-06	Glaxosmithkline Biolog Sa	Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
CN101926988B (zh)	2003-01-30	2014-06-04	诺华疫苗和诊断有限公司	抗多种脑膜炎球菌血清组的可注射性疫苗
GB0313916D0 (en)	2003-06-16	2003-07-23	Glaxosmithkline Biolog Sa	Vaccine composition
PT1961426E (pt)	2003-10-02	2011-06-28	Novartis Vaccines & Diagnostic	Vacinas combinadas contra a meningite
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
WO2005117965A1 (en)	2004-06-04	2005-12-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Methods for preparing immunogenic conjugates
GB0505518D0 (en)	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
RU2442825C2 (ru)	2005-04-18	2012-02-20	Новартис Вэксинес Энд Дайэгностикс Инк.	Иммуногенные композиции, способы получения таких композиций и плазмида, включенная в такие композиции
AU2006263965B2 (en)	2005-06-27	2012-09-13	Glaxosmithkline Biologicals S.A.	Process for manufacturing vaccines
GB0517719D0 (en) *	2005-08-31	2005-10-05	Chiron Srl	Vaccines containing pili
EP1931380A2 (en)	2005-09-01	2008-06-18	Novartis Vaccines and Diagnostics GmbH & Co. KG	Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
EP1862176A1 (de) *	2006-05-31	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) *	2006-06-01	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
GB0616226D0 (en) *	2006-08-15	2006-09-27	Novartis Ag	Processes
GB0616306D0 (en) *	2006-08-16	2006-09-27	Novartis Ag	Vaccines
GB0617602D0 (en) *	2006-09-07	2006-10-18	Glaxosmithkline Biolog Sa	Vaccine
EP2491947A3 (en)	2006-09-07	2012-10-17	GlaxoSmithKline Biologicals S.A.	Vaccine
EP2114991A1 (en) *	2007-02-07	2009-11-11	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Recombinant antigens of human cytomegalovirus (hcmv)
EP2682127A1 (en)	2007-05-02	2014-01-08	GlaxoSmithKline Biologicals S.A.	Vaccine
PE20100366A1 (es) *	2008-10-24	2010-05-21	Panacea Biotec Ltd	Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es)	2008-10-24	2010-05-21	Panacea Biotec Ltd	Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
IT1398927B1 (it)	2009-06-25	2013-03-28	Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi	Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en)	2009-10-08	2009-11-25	Glaxosmithkline Biolog Sa	Expression system
AU2011288203A1 (en)	2010-03-18	2012-08-23	Novartis Ag	Adjuvanted vaccines for serogroup B meningococcus
FR2966044B1 (fr)	2010-10-18	2012-11-02	Sanofi Pasteur	Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
WO2012072088A1 (en)	2010-12-02	2012-06-07	Bionor Immuno As	Peptide scaffold design
EP2661277A2 (en)	2011-01-05	2013-11-13	Bharat Biotech International Limited	A combination heptavalent vaccine
MX346475B (es)	2011-01-06	2017-03-22	Bionor Immuno As	Peptidos inmunogenicos monomericos y multimericos.
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
KR20140066126A (ko) *	2011-05-11	2014-05-30	리스벡 헬스케어 스웨덴 에이비	단백질 f - 라미닌 및 비트로넥틴 결합 특성을 갖는 신규한 헤모필러스 인플루엔자 부착분자
US20140234360A1 (en)	2011-09-30	2014-08-21	The United States of America, as represented by the Secretary, Dept.of Health and Human Services	Influenza vaccine
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en)	2011-11-11	2013-05-15	Novartis AG	Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
FR2985663B1 (fr) *	2012-01-17	2015-03-27	Sanofi Pasteur	Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
CA2862560A1 (en)	2012-02-01	2013-08-08	Glaxosmithkline Biologicals S.A.	Fermentation process for bordetella species
CN104159603A (zh) *	2012-03-08	2014-11-19	诺华股份有限公司	带有tlr4激动剂的联合疫苗
AU2013273482A1 (en)	2012-06-06	2014-12-11	Bionor Immuno As	Peptides derived from viral proteins for use as immunogens and dosage reactants
JP2015525794A (ja)	2012-08-06	2015-09-07	グラクソスミスクラインバイオロジカルズソシエテアノニム	乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
CA2886938A1 (en)	2012-10-12	2014-04-17	Glaxosmithkline Biologicals S.A.	Non-cross-linked acellular pertussis antigens for use in combination vaccines
AP2015008702A0 (en)	2013-03-08	2015-09-30	Crucell Holland Bv	Acellular pertussis vaccine
US9993534B2 (en)	2013-03-12	2018-06-12	Wisconsin Alumni Research Foundation	Method of treating fungal infection
MX2016001695A (es)	2013-08-05	2016-05-02	Glaxosmithkline Biolog Sa	Composiciones inmunogenas de combinacion.
WO2016012385A1 (en)	2014-07-21	2016-01-28	Sanofi Pasteur	Vaccine composition comprising ipv and cyclodextrins
MA42317B2 (fr) *	2015-09-16	2021-11-30	Lg Chemical Ltd	Composition de vaccin combinée pour administration multiple
EP3518968B1 (en)	2016-10-03	2022-01-05	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Hiv-1 env fusion peptide immunogens and their use
WO2018081832A1 (en)	2016-10-31	2018-05-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Peptide fragments from filoviruses and their uses
EP3600405A1 (en)	2017-03-24	2020-02-05	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Glycan-masked engineered outer domains of hiv-1 gp120 and their use
EA202090316A1 (ru)	2017-07-18	2020-12-08	Серум Инститьют Оф Индия Пвт Лтд.	Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения
WO2019079337A1 (en)	2017-10-16	2019-04-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
WO2020043874A1 (en)	2018-08-31	2020-03-05	Glaxosmithkline Biologicals Sa	Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle
WO2020061564A1 (en)	2018-09-23	2020-03-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
JOP20190242A1 (ar)	2018-10-12	2020-04-12	Serum Institute Of India Pvt Ltd	تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020086483A1 (en)	2018-10-22	2020-04-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant gp120 protein with v1-loop deletion
EP3972637A4 (en)	2019-05-20	2023-06-21	Soligenix, Inc.	COMPOSITIONS AND METHODS OF MANUFACTURE OF TRIVAL FILOVIRUS VACCINES
US20230109142A1 (en)	2020-02-14	2023-04-06	Immunor As	Corona virus vaccine
WO2021176409A1 (en)	2020-03-05	2021-09-10	Sanofi Healthcare India Private Limited	Preservative combination for vaccine composition
WO2022224966A1 (ja) *	2021-04-20	2022-10-27	Ｋｍバイオロジクス株式会社	６種混合液状ワクチン組成物
EP4380613A1 (en)	2021-08-03	2024-06-12	The United States of America, as represented by the Secretary, Department of Health and Human Services	Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
EP4169513A1 (en)	2021-10-19	2023-04-26	GlaxoSmithKline Biologicals S.A.	Adjuvant composition comprising sting agonists
WO2023192835A1 (en)	2022-03-27	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6013718A (ja) *	1983-07-05	1985-01-24	Chemo Sero Therapeut Res Inst	Ｂ型肝炎ワクチン
JPS60193925A (ja) *	1984-03-13	1985-10-02	Chemo Sero Therapeut Res Inst	凍結乾燥製剤化ワクチン
US4624918A (en) *	1984-07-09	1986-11-25	Genentech, Inc.	Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi)	1985-04-15	1986-04-01	Endotronics Inc	Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en)	1985-11-26	1990-01-23	Phillips Petroleum Company	Yeast production of hepatitis B surface antigen
ZA88488B (en)	1987-01-30	1988-10-26	Smith Kline Rit	Hepatitis b virus surface antigens and hybrid antigens containing them
EP0304578B1 (en)	1987-06-22	2001-10-24	Medeva Holdings Bv	Peptide comprising hepatitis B surface antigen
EP0299108B1 (en)	1987-07-17	1994-05-18	Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH	DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
JPH085804B2 (ja) *	1988-04-28	1996-01-24	財団法人化学及血清療法研究所	Ａ型及びｂ型肝炎混合アジュバントワクチン
DK0414374T3 (da)	1989-07-25	1998-03-09	Smithkline Beecham Biolog	Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
DK0427462T3 (da)	1989-11-06	1996-03-11	Smithkline Beecham Biolog	Fremgangsmåde
AU646019B2 (en)	1990-02-12	1994-02-03	Smithkline Beecham Biologicals (Sa)	Novel vaccine and method therefor
GB9007024D0 (en)	1990-03-29	1990-05-30	Imperial College	Novel vaccine
EP0563091A1 (en) *	1990-12-20	1993-10-06	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Vaccines based on hepatitis b surface antigen
CA2067003A1 (en)	1991-04-29	1992-10-30	Peter J. Kniskern	Hbsag escape mutant vaccine
JPH06503231A (ja) *	1991-09-18	1994-04-14	アムジエン・インコーポレーテツド	胆汁酸塩を含有するｂ型肝炎ワクチン製剤
SK117395A3 (en) *	1993-03-23	1996-11-06	Smithkline Beecham Biolog	Vaccine composition and manufacturing process thereof
DE69612198T3 (de)	1995-06-23	2011-08-18	Smithkline Beecham Biologicals S.A.	Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
RU2130778C1 (ru)	1998-07-31	1999-05-27	Акционерное общество закрытого типа НПК "Комбиотех Лтд"	Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko)	2000-07-05	2003-05-27	녹십자백신 주식회사	디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko)	2001-01-10	2003-10-17	주식회사 엘지생명과학	혼합 백신의 제조 방법

1993
- 1993-05-15 DE DE122010000016C patent/DE122010000016I1/de active Pending
- 1993-05-15 NZ NZ253065A patent/NZ253065A/en not_active IP Right Cessation
- 1993-05-15 CZ CZ942892A patent/CZ283910B6/cs not_active IP Right Cessation
- 1993-05-15 EP EP93912750A patent/EP0642355B1/en not_active Revoked
- 1993-05-15 KR KR1019940704215A patent/KR100287083B1/ko not_active IP Right Cessation
- 1993-05-15 DK DK97204034.9T patent/DK0835663T3/da active
- 1993-05-15 DE DE69334297T patent/DE69334297D1/de not_active Expired - Lifetime
- 1993-05-15 EP EP97204034A patent/EP0835663B1/en not_active Revoked
- 1993-05-15 UA UA94129182A patent/UA40596C2/uk unknown
- 1993-05-15 SG SG1996009149A patent/SG48365A1/en unknown
- 1993-05-15 AT AT93912750T patent/ATE168271T1/de not_active IP Right Cessation
- 1993-05-15 PT PT97204034T patent/PT835663E/pt unknown
- 1993-05-15 ES ES93912750T patent/ES2118963T3/es not_active Expired - Lifetime
- 1993-05-15 EP EP10179579A patent/EP2289548A3/en not_active Withdrawn
- 1993-05-15 CA CA002136429A patent/CA2136429C/en not_active Expired - Lifetime
- 1993-05-15 HU HU9403366A patent/HU220236B/hu unknown
- 1993-05-15 DE DE69319728T patent/DE69319728T2/de not_active Revoked
- 1993-05-15 RU RU94046145/13A patent/RU2160120C2/ru active IP Right Maintenance
- 1993-05-15 WO PCT/EP1993/001276 patent/WO1993024148A1/en not_active Application Discontinuation
- 1993-05-15 EP EP09171545A patent/EP2156845A1/en not_active Withdrawn
- 1993-05-15 DE DE122010000015C patent/DE122010000015I1/de active Pending
- 1993-05-15 ES ES97204034T patent/ES2334181T3/es not_active Expired - Lifetime
- 1993-05-15 SK SK1421-94A patent/SK280702B6/sk not_active IP Right Cessation
- 1993-05-15 JP JP50016294A patent/JP3626996B2/ja not_active Expired - Lifetime
- 1993-05-15 DK DK93912750T patent/DK0642355T3/da active
- 1993-05-15 AT AT97204034T patent/ATE444079T1/de active
- 1993-05-15 AU AU43156/93A patent/AU4315693A/en not_active Abandoned
- 1993-05-20 MY MYPI93000939A patent/MY110665A/en unknown
- 1993-05-20 AP APAP/P/1993/000530A patent/AP567A/en active
- 1993-05-21 SI SI9300271A patent/SI9300271A/sl not_active IP Right Cessation
- 1993-05-21 IL IL10577093A patent/IL105770A/en not_active IP Right Cessation
- 1993-05-21 MX MX9302982A patent/MX9302982A/es active IP Right Grant
- 1993-05-21 MA MA23192A patent/MA22894A1/fr unknown
- 1993-05-22 CN CNB031332374A patent/CN1313152C/zh not_active Expired - Lifetime
- 1993-05-22 CN CNB931073197A patent/CN1136918C/zh not_active Ceased
1994
- 1994-11-22 FI FI945483A patent/FI945483A/fi not_active Application Discontinuation
- 1994-11-22 NO NO944475A patent/NO309675B1/no not_active IP Right Cessation
1996
- 1996-11-25 US US08/755,927 patent/US6013264A/en not_active Expired - Lifetime
1997
- 1997-03-24 AU AU16480/97A patent/AU709406C/en not_active Expired
1998
- 1998-11-30 HK HK98112444A patent/HK1011290A1/xx not_active IP Right Cessation
- 1998-11-30 HK HK00100138.3A patent/HK1021142A1/xx not_active IP Right Cessation
2002
- 2002-06-25 AU AU50629/02A patent/AU785433B2/en not_active Expired
2007
- 2007-03-16 AU AU2007201162A patent/AU2007201162A1/en not_active Abandoned
2010
- 2010-01-22 AU AU2010200249A patent/AU2010200249B2/en not_active Expired
- 2010-03-03 LU LU91659C patent/LU91659I2/fr unknown
- 2010-03-03 LU LU91658C patent/LU91658I2/fr unknown
2011
- 2011-03-02 CY CY1100003A patent/CY2614B2/xx unknown

Also Published As

Publication number	Publication date
EP0835663B1 (en)	2009-09-30
AP567A (en)	1996-11-25
LU91659I2 (fr)	2010-05-03
IL105770A0 (en)	1993-09-22
IL105770A (en)	1998-08-16
EP0835663A2 (en)	1998-04-15
SK142194A3 (en)	1995-08-09
CN1136918C (zh)	2004-02-04
AU2010200249B2 (en)	2012-01-12
RU94046145A (ru)	1997-03-27
EP2289548A3 (en)	2012-08-08
EP2289548A2 (en)	2011-03-02
JP3626996B2 (ja)	2005-03-09
EP0835663A3 (en)	1999-03-03
AU4315693A (en)	1993-12-30
HK1021142A1 (en)	2000-06-02
HK1011290A1 (en)	1999-07-09
RU2160120C2 (ru)	2000-12-10
CZ289294A3 (en)	1995-09-13
KR950701822A (ko)	1995-05-17
HU220236B (hu)	2001-11-28
MA22894A1 (fr)	1993-12-31
DE69319728D1 (de)	1998-08-20
HU9403366D0 (en)	1995-02-28
CA2136429A1 (en)	1993-12-09
AU2007201162A1 (en)	2007-04-19
SI9300271A (en)	1993-12-31
MY110665A (en)	1999-01-30
FI945483A0 (fi)	1994-11-22
AU5062902A (en)	2002-08-08
CA2136429C (en)	2001-12-11
AU709406B2 (en)	1999-08-26
ES2334181T3 (es)	2010-03-05
EP2156845A1 (en)	2010-02-24
AP9300530A0 (en)	1993-07-31
EP0642355A1 (en)	1995-03-15
CN1085450A (zh)	1994-04-20
KR100287083B1 (ko)	2001-04-16
SG48365A1 (en)	1998-04-17
SK280702B6 (sk)	2000-06-12
FI945483A (fi)	1995-01-20
US6013264A (en)	2000-01-11
CZ283910B6 (cs)	1998-07-15
DE122010000015I1 (de)	2010-07-08
NO944475L (no)	1995-01-18
JPH07508267A (ja)	1995-09-14
ATE168271T1 (de)	1998-08-15
WO1993024148A1 (en)	1993-12-09
ATE444079T1 (de)	2009-10-15
AU2010200249A1 (en)	2010-02-11
DE69319728T2 (de)	1999-02-04
PT835663E (pt)	2010-01-04
AU709406C (en)	2004-04-08
DE69334297D1 (de)	2009-11-12
NO944475D0 (no)	1994-11-22
CN1623602A (zh)	2005-06-08
CY2614B2 (en)	2012-01-25
ES2118963T3 (es)	1998-10-01
AU1648097A (en)	1997-05-29
NZ253065A (en)	1996-10-28
HUT71791A (en)	1996-02-28
CN1313152C (zh)	2007-05-02
MX9302982A (es)	1993-12-01
UA40596C2 (uk)	2001-08-15
DK0642355T3 (da)	1998-11-30
LU91658I2 (fr)	2010-05-03
AU785433B2 (en)	2007-05-31
EP0642355B1 (en)	1998-07-15
DE122010000016I1 (de)	2010-07-08
DK0835663T3 (da)	2010-02-01

Legal Events

Date	Code	Title	Description
2013-06-10	MK1K	Patent expired

Publication	Publication Date	Title
AP567A (en)	1996-11-25	Combined vaccines comprising hepatitis B surface antigen and other antigens.
CA2221511C (en)	2013-01-08	Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
US10092640B2 (en)	2018-10-09	Combination heptavalent vaccine
BRPI9712917B1 (pt)	2019-12-03	composição de vacina compreendendo toxóides diftérico, tetânico e pertussis.
AU2012202099A1 (en)	2012-05-03	Combined vaccines comprising hepatitis B surface antigen and other antigens
US8623380B2 (en)	2014-01-07	Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
RU2287344C2 (ru)	2006-11-20	Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека